Corvus Pharmaceuticals (CRVS) vs CryoPort (CYRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
CryoPort (CYRX) has outperformed Corvus Pharmaceuticals (CRVS) over the past year, gaining 74.5% versus a gain of 45.1%. Over five years, CRVS leads with a +112.5% price change compared with -75.3% for CYRX. Corvus Pharmaceuticals is the larger company by market cap ($885.0 million vs $878.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRVS | CYRX |
|---|---|---|
| Share price | $10.52 | $17.35 |
| Market cap | $884.95M | $878.76M |
| 1-day change | +3.04% | +2.66% |
| YTD return | +36.62% | +80.73% |
| 1-year return | +45.10% | +74.55% |
| 5-year return | +112.53% | -75.31% |
| EPS (TTM) | $-0.62 | $-0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.95 | $18.36 |
| 52-week low | $6.39 | $7.61 |
| Distance from 52-week high | -60.96% | -5.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +215.02% | +13.37% |
| Average volume | 982.52K | 643.08K |
| Shares outstanding | 84.12M | 50.65M |
| Employees | 37 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed CRVS by 29.4 percentage points over the past year.
About Corvus Pharmaceuticals
CRVS stock →Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
CRVS vs CYRX FAQ
Which is bigger, Corvus Pharmaceuticals or CryoPort?
Corvus Pharmaceuticals (CRVS) is larger, with a market capitalization of $884.95M compared with $878.76M for CryoPort (CYRX).
Which stock has performed better over the past year, CRVS or CYRX?
CYRX returned +74.55% over the past 12 months, compared with +45.10% for CRVS (price return, excluding dividends). Past performance does not predict future results.
Are Corvus Pharmaceuticals and CryoPort in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.